GSK Plc agreed to buy an experimental medicine to treat liver disease for as much as $2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines.  The treatment developed by Boston ...

Management flagged the importance of mitigating new tariffs, navigating the loss of exclusivity for major products, and sustaining growth from its expanding medicine pipeline. Johnson & Johnson ...

LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...

Disc Medicine, Inc. announced significant advancements ... efforts for bitopertin as well as development of the rest of our pipeline. We expect data from ongoing trials of DISC-0974, the Phase ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

Strategic priorities did not shift markedly, with primary attention on INO-3107's advancement and the next-generation DNA medicine platform. Management acknowledged the evolving nature of tariffs ...